Abstract 655P
Background
ADCs are a rapidly emerging modality of systemic anti-cancer treatment with 11 agents FDA approved and more under investigation.
Methods
Patients that received at least 1 dose of ADC in phase 1-3 trials at SCRI UK between 2012-2023 were included. Patient and tumor characteristics, toxicity and outcomes overall and for subgroups of interest were assessed using descriptive statistics and cox regression.
Results
102 patients from 16 trials (8 phase 1, 8 phase 2-3) of 13 different ADCs were included (median age 62 (32-81), male 32.4%). Main tumor types were breast (n=40, 38.5%) and gynecological (n=19, 18.3%). Median number of prior treatment lines was 3 (1-18). Payloads comprised alkylating agents (AA, n=3), microtubule inhibitors (MTI, n=8) or a topoisomerase inhibitor (Topo-I, n=2). 3 ADCs targeted an oncogene (HER2) vs tumor associated antigens (TAA). TRAEs of any grade occurred in 88% of patients (grade 3-4 25%). Colitis occurred in 3.8% (2.9%), ILD 3.8% (1.0%), neuropathy 26.0% (0%), eye toxicity 22.1% (0%) and hepatotoxicity 27.8% (4.8%). Most toxicities occurred early (
Conclusions
ADC activity is seen across different tumors with higher efficacy when oncogene targeted. Identification of timelines of expected toxicities is critical for clinical management and mitigation strategies.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
R. Woodford, A. Cammarota, K. Joshi, R.M. Grochot: Financial Interests, Institutional, Full or part-time Employment: HCA International. A. Williams: Financial Interests, Institutional, Full or part-time Employment: HCA International; Financial Interests, Personal, Advisory Role: Ellipses Pharma UK. E. Fontana: Financial Interests, Personal, Invited Speaker: Caris Life Science, Repair Therapeutics; Financial Interests, Personal, Other, Conference attendance: Sapience Pharma; Financial Interests, Personal, Invited Speaker, Conference Attendance: Bicycles Therapeutics; Financial Interests, Personal, Full or part-time Employment: Hospital Corporation of America (HCA) International; Financial Interests, Personal, Officer: EORTC; Financial Interests, Institutional, Coordinating PI: Repair Therapeutics, Amgen, Taiho Pharmaceutical; Financial Interests, Institutional, Local PI: Bicycle Therapeutics, Artios Pharma, Seagen, Nurix Therapeutics, BioNTech SE, Relay Therapeutics, Pfizer, Roche, Daiichi Sankyo, Gilead Science, Basilea Pharmaceutica, Jiangsu Hengrui Medicine, Mereo Biopharma, Hutchmed, Merus, Crescendo Biologics, GSK plc, BeiGene, Turning Point Therapeutics, Sapience Pharma, Arcus Bioscience, Exelixis, Nerviano Medica, Elipsees, Deciphera, Ribon Therapeutics. All other authors have declared no conflicts of interest.
Resources from the same session
683TiP - A phase I study of PARP inhibitor (niraparib) plus HSP90 inhibitor (pimitespib) in solid tumors: The NiraPim (EPOC2102) study
Presenter: Hiromichi Nakajima
Session: Poster session 01
684TiP - A phase I, open-label, multicenter, dose escalation and expansion study of HM97662 (EZH1/2 dual inhibitor) as a single agent in patients with advanced or metastatic solid tumors
Presenter: Bhumsuk Keam
Session: Poster session 01
685TiP - A phase I, multicenter trial (“KinLET”) of [177Lu]Lu-edotreotide for treatment of somatostatin receptor positive solid tumors or lymphoma, in patients two to less than 18 years of age
Presenter: Maria Cristina Mata Fernandez
Session: Poster session 01
687TiP - A phase I, first in human study of TORL-4-500 in patients with advanced cancer
Presenter: Jonathan Goldman
Session: Poster session 01
688TiP - Phase I dose escalation trial to evaluate safety and preliminary efficacy of ACR246, an innovative 5T4- antibody drug conjugate (ADC), in patients (pts) with advanced solid tumors
Presenter: Xihui Hu
Session: Poster session 01
689TiP - A phase I/IIa trial of Aurora-A inhibitor (JAB-2485) in adult patients with advanced solid tumors
Presenter: Vaia Florou
Session: Poster session 01
690TiP - HERTHENA-PanTumor01: A global phase II trial of HER3-DXd in metastatic solid tumors
Presenter: Thomas Powles
Session: Poster session 01
691TiP - PYNNACLE phase II trial of rezatapopt (PC14586) in solid tumors with a TP53 Y220C mutation
Presenter: Alison Schram
Session: Poster session 01
722P - Long-term patient-reported outcomes (PROs) with atezolizumab (atezo) + bevacizumab (bev) and chemotherapy (CT) for metastatic, persistent or recurrent cervical cancer (R/M CC): BEATcc (ENGOT-Cx10/GEICO 68-C/JGOG1084/GOG-3030) randomised phase III trial
Presenter: Laurence Gladieff
Session: Poster session 01